These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29410344)

  • 21. Dermatology clinical trials and drug development.
    Ehrenberger HE; Joshi TG
    Dermatol Nurs; 2003 Oct; 15(5):428-34. PubMed ID: 14619320
    [No Abstract]   [Full Text] [Related]  

  • 22. Drugs with FDA accelerated approval often have weak evidence, study finds.
    Dyer O
    BMJ; 2017 Jun; 357():j2905. PubMed ID: 28615167
    [No Abstract]   [Full Text] [Related]  

  • 23. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Considerations in characterizing real-world data relevance and quality for regulatory purposes: A commentary.
    Girman CJ; Ritchey ME; Zhou W; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):439-442. PubMed ID: 30515910
    [No Abstract]   [Full Text] [Related]  

  • 25. New fee structure proposed by FDA might lead to more talk.
    Waters H
    Nat Med; 2011 Oct; 17(10):1159. PubMed ID: 21988966
    [No Abstract]   [Full Text] [Related]  

  • 26. Resuscitating Cardiovascular Drug Development.
    Helmy K; Harrington RA; Kocher B
    JAMA Cardiol; 2017 Dec; 2(12):1295-1296. PubMed ID: 29117283
    [No Abstract]   [Full Text] [Related]  

  • 27. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia.
    Sekeres MA; Steensma DP
    J Clin Oncol; 2012 Nov; 30(33):4061-3. PubMed ID: 23008302
    [No Abstract]   [Full Text] [Related]  

  • 28. US Food and Drug Administration and design of drug approval studies.
    Woloshin S; Schwartz LM; Frankel B; Faerber A
    JAMA; 2014 Nov; 312(20):2163-5. PubMed ID: 25423223
    [No Abstract]   [Full Text] [Related]  

  • 29. New law to improve animal drug review.
    FDA Consum; 2004; 38(1):5. PubMed ID: 15032189
    [No Abstract]   [Full Text] [Related]  

  • 30. Where do our priorities lie?
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2007 Jul; 4(7):353. PubMed ID: 17607292
    [No Abstract]   [Full Text] [Related]  

  • 31. FDA approvals of old drugs put new pressure on payers.
    Silverman E
    Manag Care; 2011 May; 20(5):30-1. PubMed ID: 21667624
    [No Abstract]   [Full Text] [Related]  

  • 32. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
    Tsimberidou AM; Braiteh F; Stewart DJ; Kurzrock R
    J Clin Oncol; 2009 Dec; 27(36):6243-50. PubMed ID: 19826112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Letter from the Commissioner's Office at the US FDA.
    Vernon JA
    Pharmacoeconomics; 2007; 25(4):267-8. PubMed ID: 17402801
    [No Abstract]   [Full Text] [Related]  

  • 34. Radioactive drugs emerge from the shadows to storm the market.
    Dolgin E
    Nat Biotechnol; 2018 Dec; 36(12):1125-1127. PubMed ID: 30520873
    [No Abstract]   [Full Text] [Related]  

  • 35. Bill to boost medical research funding and speed drug approval passes US house.
    McCarthy M
    BMJ; 2016 Dec; 355():i6498. PubMed ID: 27908875
    [No Abstract]   [Full Text] [Related]  

  • 36. Does neurology need a faster FDA?
    Burton A
    Lancet Neurol; 2014 Aug; 13(8):760-1. PubMed ID: 25030510
    [No Abstract]   [Full Text] [Related]  

  • 37. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category.
    Glasziou PP
    Med J Aust; 1995 Jan; 162(1):33-6. PubMed ID: 7605432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
    Oo C; Rusch LM
    J Clin Pharmacol; 2016 Mar; 56(3):257-9. PubMed ID: 26211513
    [No Abstract]   [Full Text] [Related]  

  • 39. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the cardiovascular safety of diabetes therapies.
    Goldfine AB
    N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.